Histological spectrum of ependymomas and correlation of p53 and Ki- 67 expression with ependymoma grade and subtype

Indian Journal of Cancer

Volumn 41, Issue 2, 2004, Pages 66-71

  Vaishali, Suri S ^a   Tatke, M ^a   Daljit, Singh ^a   Ajay, Sharma ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Ependymoma; Immunohistochemistry; Ki 67; p53

Indexed keywords

ANTIBODY; KI 67 ANTIGEN; PARAFFIN; PROTEIN P53; SYNAPTOPHYSIN;

ARTICLE; CHOROID PLEXUS PAPILLOMA; CORRELATION ANALYSIS; EPENDYMOBLASTOMA; EPENDYMOMA; HISTOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INCIDENCE; MORPHOLOGY; NEUROEPITHELIOMA; OLIGODENDROGLIOMA; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; EPENDYMOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; INFANT; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SPECTRUM ANALYSIS; STATISTICS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4444320442     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Applegate GL, Marymont MH. Intracranial ependymomas: A review. Cancer Invest 1998;16:588-93.
2. Bigner DD, McLendon RE, Bruner JM, editors. Rissel and Rubinstein's pathology of tumors of the nervous system. 6th Ed. London: Arnold 1998.
3. Bouffet E, Perilongo G, Canete A, Massimino Mlntracranial ependymomas in children: A critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 1998;30:319-29.
4. Hamilton RL, Pollack IF. The molecular biology of ependymomas. Brain Pathol 1997;7:807-22.
5. Kleihues P, Cavenee WK. Tumors of the nervous system. Pathology and genetics. World Health Organization classification of the tumours. Lyon, France: IARC Press 2000. p. 72-81.
6. Tomita T, McLone DG, Das L, Brand WN. Benign ependymomas of the posterior fossa in childhood. Pediatr Neurosci 1988;14: 277-85.
7. Sala F, Talacchi A, Mazza C, Prisco R, Ghimenton C, Bricolo A. Prognostic factors in childhood intracranial ependymomas: The role of age andtumor location. Pediatr Neurosurg 1998;28: 135-42. Review.
8. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.
9. Jin YT, Kayser S, Kemp BL, Ordonez NG, Tucker SL, Clayman GL, et al. The prognostic significance of the biomarkers p21WAF11CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma. Cancer 1998;82:2154-65.
10. Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda MA, Bellot J, et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997;80:1472-81.
11. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
12. rd. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype. Mod Pathol 1998;11:464-70.
13. Suzuki S, Oka H, Kawano N, Tanaka S, Utsuki S, Fujii K. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas. Brain Tumor Pathol 2001;18:151-4.
14. Verstegen MJ, Leenstra DT, Ijist-Keizers H, Bosch DA. Proliferation- and apoptosis-related proteins in intracranial ependymomas: An immunohistochemical analysis. J Neurooncol 2002;56: 21-8.
15. Prayson RA. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: A study of 41 cases. Am J Clin Pathol 1998;110:629-34.
16. Gerszten PC, Pollack IF, Martinez AJ, Lo KH, Janosky J, Albright AL. Intracranial ependymomas of childhood. Lack of correlation of histopathology and clinical outcome. Pathol Res Pract 1996;192:515-22.
17. Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright AL, et al. Intracranial ependymomas of childhood: Long-term outcome and prognostic factors. Neurosurgery 1995;37:655-66; discussion 666-7.
18. Schiffer D, Chio A, Giordana MT, Migheli A, Palma L, Polio B, et al. Histologic prognostic factors in ependymoma. Childs Nerv Syst 1991;7:177-82.
19. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 2000;177:72-82.
20. Iwasaki Y, Hida K, Sawamura Y, Abe H. Spinal intramedullary ependymomas: Surgical results and immunohistochemical analysis of tumour proliferation activity. Br J Neurosurg 2000;14:331-6.
21. Bennetto L, Foreman N, Harding B, Hayward R, Ironside J, Love S, et al. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol 1998;24:434-40.
22. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: A study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol (Berl) 1994;87:47-54.
23. Rezai AR, Woo HH, Lee M, Cohen H, Zagzag D, Epstein FJ. Disseminated ependymomas of the central nervous system. J Neurosurg 1996;85:618-24.
24. Schroder R, Ploner C, Ernestus RI. The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index. Neurosurg Rev 1993;16:145-50.
25. Fink KL, Rushing EJ, Schold SC Jr, Nisen PD. Infrequency of p53 gene mutations in ependymomas. J Neurooncol 1996;27:111-5.
26. Nozaki M, Tada M, Matsumoto R, Sawamura Y, Abe H, Iggo RD. Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: Reappraisal by yeast functional assay. Acta Neuropathol (Berl) 1998;95: 291-6.